Neuphoria Therapeutics (NASDAQ:NEUP) Upgraded to “Hold” at Zacks Research

Zacks Research upgraded shares of Neuphoria Therapeutics (NASDAQ:NEUP) from a strong sell rating to a hold rating in a research note issued to investors on Tuesday morning,Zacks.com reports.

Several other research analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Neuphoria Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 23rd. HC Wainwright decreased their target price on shares of Neuphoria Therapeutics from $21.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, December 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $21.00.

Neuphoria Therapeutics Price Performance

Shares of NASDAQ:NEUP opened at $4.00 on Tuesday. Neuphoria Therapeutics has a 1 year low of $3.64 and a 1 year high of $21.40. The company has a market cap of $21.52 million, a P/E ratio of -0.82 and a beta of 0.52. The stock’s fifty day moving average price is $4.05 and its 200-day moving average price is $7.51.

Neuphoria Therapeutics (NASDAQ:NEUP) last released its quarterly earnings data on Friday, November 14th. The company reported ($4.41) EPS for the quarter, missing the consensus estimate of ($0.55) by ($3.86). On average, sell-side analysts anticipate that Neuphoria Therapeutics will post -1.56 earnings per share for the current year.

Institutional Investors Weigh In On Neuphoria Therapeutics

A number of hedge funds have recently modified their holdings of the business. Persistent Asset Partners Ltd purchased a new stake in shares of Neuphoria Therapeutics in the 3rd quarter worth $58,000. Millennium Management LLC bought a new stake in Neuphoria Therapeutics during the third quarter valued at about $216,000. Finally, FNY Investment Advisers LLC purchased a new stake in Neuphoria Therapeutics in the fourth quarter worth about $102,000. Institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.